Abbott Laboratories (ABT) Competitors

$104.09
-0.78 (-0.74%)
(As of 05/17/2024 ET)

ABT vs. PFE, NVS, AZN, SNY, VRTX, REGN, GSK, BMY, ABBV, and ZTS

Should you be buying Abbott Laboratories stock or one of its competitors? The main competitors of Abbott Laboratories include Pfizer (PFE), Novartis (NVS), AstraZeneca (AZN), Sanofi (SNY), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), GSK (GSK), Bristol-Myers Squibb (BMY), AbbVie (ABBV), and Zoetis (ZTS). These companies are all part of the "pharmaceutical preparations" industry.

Abbott Laboratories vs.

Pfizer (NYSE:PFE) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, institutional ownership, media sentiment, valuation and risk.

Pfizer received 571 more outperform votes than Abbott Laboratories when rated by MarketBeat users. However, 69.60% of users gave Abbott Laboratories an outperform vote while only 69.06% of users gave Pfizer an outperform vote.

CompanyUnderperformOutperform
PfizerOutperform Votes
1489
69.06%
Underperform Votes
667
30.94%
Abbott LaboratoriesOutperform Votes
918
69.60%
Underperform Votes
401
30.40%

Pfizer has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Pfizer currently has a consensus target price of $35.86, indicating a potential upside of 25.20%. Abbott Laboratories has a consensus target price of $121.50, indicating a potential upside of 16.73%. Given Abbott Laboratories' higher probable upside, research analysts plainly believe Pfizer is more favorable than Abbott Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pfizer
0 Sell rating(s)
9 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.40
Abbott Laboratories
0 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.67

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 0.1% of Pfizer shares are owned by company insiders. Comparatively, 1.1% of Abbott Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Pfizer pays an annual dividend of $1.68 per share and has a dividend yield of 5.9%. Abbott Laboratories pays an annual dividend of $2.20 per share and has a dividend yield of 2.1%. Pfizer pays out -2,799.5% of its earnings in the form of a dividend. Abbott Laboratories pays out 68.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has increased its dividend for 15 consecutive years and Abbott Laboratories has increased its dividend for 53 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Pfizer had 28 more articles in the media than Abbott Laboratories. MarketBeat recorded 41 mentions for Pfizer and 13 mentions for Abbott Laboratories. Pfizer's average media sentiment score of 1.13 beat Abbott Laboratories' score of 0.42 indicating that Abbott Laboratories is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pfizer
17 Very Positive mention(s)
5 Positive mention(s)
13 Neutral mention(s)
2 Negative mention(s)
4 Very Negative mention(s)
Neutral
Abbott Laboratories
10 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Abbott Laboratories has lower revenue, but higher earnings than Pfizer. Pfizer is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$58.50B2.77$2.12B-$0.06-477.25
Abbott Laboratories$40.11B4.51$5.72B$3.2132.43

Abbott Laboratories has a net margin of 13.96% compared to Abbott Laboratories' net margin of -0.56%. Pfizer's return on equity of 20.18% beat Abbott Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Pfizer-0.56% 8.64% 3.70%
Abbott Laboratories 13.96%20.18%10.60%

Summary

Abbott Laboratories beats Pfizer on 14 of the 20 factors compared between the two stocks.

Get Abbott Laboratories News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABT vs. The Competition

MetricAbbott LaboratoriesPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$181.08B$6.75B$5.35B$18.08B
Dividend Yield2.10%2.62%44.08%3.44%
P/E Ratio32.4310.95106.3122.53
Price / Sales4.51259.132,361.3010.30
Price / Cash16.4835.9136.8819.48
Price / Book4.645.825.496.01
Net Income$5.72B$128.15M$108.83M$966.65M
7 Day Performance-0.62%1.47%1.42%1.85%
1 Month Performance-2.98%4.85%4.96%6.59%
1 Year Performance-4.44%-3.62%7.85%23.69%

Abbott Laboratories Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PFE
Pfizer
4.9959 of 5 stars
$28.20
-0.2%
$36.00
+27.7%
-21.5%$159.66B$58.50B-469.8488,000
NVS
Novartis
2.0413 of 5 stars
$100.21
+0.6%
$115.00
+14.8%
+2.2%$204.83B$47.73B13.5276,057
AZN
AstraZeneca
2.4267 of 5 stars
$77.61
+0.8%
$81.00
+4.4%
+3.6%$240.63B$45.81B38.0489,900Analyst Revision
SNY
Sanofi
2.8925 of 5 stars
$48.69
-2.8%
$55.00
+13.0%
-9.6%$123.17B$46.61B24.4786,088Analyst Revision
VRTX
Vertex Pharmaceuticals
4.1627 of 5 stars
$418.99
+0.0%
$432.18
+3.1%
+31.2%$108.29B$9.87B30.165,400Analyst Upgrade
REGN
Regeneron Pharmaceuticals
4.0624 of 5 stars
$968.00
+1.3%
$981.71
+1.4%
+31.4%$106.25B$13.10B28.6013,450Analyst Forecast
Insider Selling
News Coverage
GSK
GSK
2.2681 of 5 stars
$44.67
+1.2%
N/A+27.7%$92.58B$30.74B16.1870,200News Coverage
BMY
Bristol-Myers Squibb
4.9975 of 5 stars
$44.75
+2.5%
$60.00
+34.1%
-33.0%$90.71B$45.53B-14.4434,100
ABBV
AbbVie
4.5639 of 5 stars
$160.38
0.0%
$174.31
+8.7%
+16.0%$283.21B$54.40B47.5950,000Analyst Forecast
Short Interest ↑
Analyst Revision
News Coverage
ZTS
Zoetis
4.7443 of 5 stars
$168.13
+1.9%
$211.75
+25.9%
-3.1%$76.72B$8.54B32.4014,100

Related Companies and Tools

This page (NYSE:ABT) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners